Immuron Ltd — Regulatory Filings 2005

Mar 22, 2005

March 23rd 2005

Company Announcement Office Australian Stock Exchange Ltd (ASX) $4^th$ Floor, 20 Bridge Street Sydney NSW 2000

Dear Sir/Madam,

Please find herewith a company announcement "Appointment Of Marketing Manager" for release and distribution to the market immediately.

On Behalf Of ANADIS LIMITED

CONOR GRAHAM Managing Director & CEO

Marketing Manager Appointed to focus on Travelan

Anadis Limited (ASX:ANX) is pleased to welcome our new Sales and Marketing Manager Mr. David Lvon. David joins Anadis at this time to focus on the National marketing of Travelan his employment coinciding with the appointment of Innovex Australia as Anadis' nation-wide sales force for Travelan (see announcement dated 16^th March $2005$ )

Travellers' Diarrhoea is the number one health problem in international travel in terms of frequency and economic impact. Travelan, a non-antibiotic natural preparation, is the first product to actually help reduce the risk of being affected by Traveller's Diarrhoea.

David Lyon has been involved in various Sales and Marketing positions over the last 24 years, working in both local and overseas markets, managing a diverse portfolio of health related products and brands. His most recent position was that of Sales and Marketing Manager for a TGA licensed, GMP compliant pharmaceutical and healthcare company, offering contract product development and manufacturing services for Australian and international customers. David also adds resources to Anadis' Nutritional division and will also be involved in the growth of Anadis internationally.

Anadis sees the combination of a specialized marketing focus for Travelan internally, and a high profile national sales force, as key milestones in the establishment of Travelan within Australia, before its overseas distribution. Travelan is currently in the process of international registration in the United States, the United Kingdom, the European Union and New Zealand. The vast Asian market is one of particular significance to Anadis, and negotiations are underway for positioning this product into a selection of these key markets

Travelan for personal use, will soon be available for secure world wide purchase through the internet at www.travelan.com.au.

Anadis - Delivering On The Promise Of Biotechnology

Anadis Ltd. is a Melbourne based biopharmaceutical company, focusing on Nutraceutical and Pharmaceutical products derived from bovine colostrum. Travelan has been proven in hospital clinical trials to significantly decrease the risk of Travelers Diarrhoea and the symptoms of gastrointestinal disorders. Travelan is prepared from bovine colostrum, from cows hyper-immunized against common strains of $E.$ coli – the most frequent cause of Travelers Diarrhoea and works through the process of passive immunity transfer.

Travelan

EV-71 - a product against Enterovirus 71, a polio like disease affecting children in Taiwan and other parts of Asia, currently in the process of commercialisation; Pyloran, which has been clinically proven to reduce levels of bacteria in the stomach and reduce the symptoms of H.pylori associated gastritis - Anadis is also in early development of a H.pylori vaccine; Respiratory Protection technologies, a project in conjunction with the Australian Defence Forces and US Bio-Defence Organisations, initially focused on shortterm immediate protection from airborne bacteria such as Anthrax and Plague, future civilian applications include Hay Fever and Asthma. Bio-Shield 10 a range of "bioshielding" technologies which protect delicate molecules, enzymes and proteins, initially targeted for use in the pro-biotic market, and research has begun into an Immune Stimulating Infant Formula initially for the Asian market.

For more information please contact:

Conor Graham - CEO & MD

Email: conor.g@anadis.com.au Tel: +61 3 9358 6388 $\alpha$ r Arie Nudel - Investor Relations Email: arie.n@anadis.com.au Tel: +61 3 9358 6388 or David Lyon - Sales Manager Email: david.l@ anadis.com.au Tel: +61 3 9358 6388

Fax: +61 3 9358 6399